Accrued Expenses and Other
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Additional paid-in capital
Amortization of debt discount
Restricted Stock [Member]
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Net loss per common share - basic (in dollars per share)
Cash and cash equivalents
Cash and cash equivalents
Accounts payable, accrued expenses and other liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Accrued interest on convertible debt - related party
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Changes in operating assets and liabilities:
Commitments and Contingencies
Common stock, shares authorized (in shares)
Common stock, issued (in shares)
Issuance of common stock (in shares)
Common stock, outstanding (in shares)
Common stock, $0.001 par value; 150,000,000 shares authorized at September 30, 2023 and December 31, 2022, 61,848,657 and 59,426,005 issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Convertible Preferred Stock [Member]
Total current liabilities
Liabilities, Current
Current liabilities:
Liabilities, Current [Abstract]
Convertible Line of Credit - Related Party
Convertible Notes Payable - Related Party
Debt financing arrangement
Interest rate on short term loans
Effective interest rate
Short term borrowing effective interest rate
Debt Instrument, Interest Rate, Effective Percentage
Interest rate compounded annually
Short term borrowing interest rate
Maturity date
Borrowings repayment due date
Debt Instrument, Name [Domain]
Convertible Notes Payable - Related Party [Abstract]
Debt Instrument [Axis]
Debt Instrument [Line Items]
Schedule of Long-term Debt Instruments [Table]
Common stock reserved for future issuance (in shares)
Change in fair value of derivative
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net
Derivative liabilities (Note 4)
Fair value of derivative liability
Derivative Liability - Contingent Interest
Balance
Balance
Net loss per common share - diluted (in dollars per share)
Amortized expense
Total stock-based compensation expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense
Stock-Based Compensation Expense [Abstract]
Shares issued (in shares)
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets by Major Class [Axis]
General and administrative
General and Administrative Expense [Member]
General and Administrative [Member]
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Interest expense
Amortization of interest expense
Accrued interest expense
Interest Expense, Debt
Additional interest expense
Interest Expense, Other
Total liabilities
Liabilities
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
Liabilities and Equity
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
Liabilities and Equity [Abstract]
Line of credit
Line of credit
Convertible Line of Credit - Related Party [Abstract]
Line of Credit Facility [Line Items]
Line of Credit Facility [Table]
Convertible Line of Credit - Related Party [Member]
Line of Credit [Member]
Convertible Notes Payable - Related Party [Member]
Equity ownership percentage
Related Party [Axis]
Related Party, Type [Axis]
Net cash flows from financing activities
Net Cash Provided by (Used in) Financing Activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash from operating activities
Net Cash Provided by (Used in) Operating Activities
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Net loss
Net loss
Net loss applicable to common stockholders
Net Income (Loss) Available to Common Stockholders, Basic
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounting Standards Update and Change in Accounting Principle [Table]
Total other income (expense)
Nonoperating Income (Expense)
Other income (expense):
Total operating loss
Operating Income (Loss)
Series A 12% convertible preferred stock, shares authorized (in shares)
Series A 12% convertible preferred stock, shares issued (in shares)
Series A 12% convertible preferred stock, shares outstanding (in shares)
Preferred stock dividends
Preferred Stock Dividends and Other Adjustments
Net proceeds from convertible line of credit - related party
Proceeds from lines of credit
Initial cash investment
Related Party [Domain]
Related Party, Type [Domain]
Accumulated deficit
Components of Stock-Based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Security deposit
Series A 12% Convertible Preferred Stock [Member]
Series A Preferred Stock [Member]
Forfeited/cancelled (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Granted (in shares)
Restricted stock awards granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Outstanding at beginning of period (in shares)
Outstanding at end of period (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Unrecognized compensation cost
Forfeited/cancelled (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Weighted-average grant-date fair value of options granted (in dollars per share)
Outstanding at end of period (in shares)
Outstanding at beginning of period (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Outstanding at beginning of period (in dollars per share)
Outstanding at beginning of period (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Expected dividend
Expected dividend rate
Expected volatility
Expected volatility of the underlying stock
Risk free interest rate
Risk-free interest rate
Award Type [Domain]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]
Stockholders' equity (deficit):
Equity, Attributable to Parent [Abstract]
Common Stock
Equity [Text Block]
Warrants to purchase common stock (in shares)
Total current assets
Assets, Current
Current assets:
Assets, Current [Abstract]
Warrants [Member]
Weighted average common shares outstanding - diluted (in shares)
Weighted average common shares outstanding - basic (in shares)
Common Stock [Member]
Research and development
Convertible Note Payable [Member]
Preferred Stock [Member]
Total assets
Assets
Interest income
Other liabilities
Financial Instruments [Domain]
Stock-Based Compensation
Statement [Table]
Antidilutive Securities, Name [Domain]
ASSETS
Assets [Abstract]
Statement [Line Items]
Roll Forward of Derivative Liability - Contingent Interest
Roll Forward of Derivative Liability [Roll Forward]
Common Stock Warrant Activity
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Level 1 [Member]
Level 2 [Member]
Level 3 [Member]
Estimated fair value of asset contributed to joint venture
Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure
Noncash right to use lease asset
Common Stock [Abstract]
Fair Value of Financial Instruments
Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)
Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)
Ending balance (in shares)
Beginning balance (in shares)
Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)
Class of Stock [Domain]
Common Stock Warrants Purchase Agreement [Abstract]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock purchase warrants issued in connection with related party line of credit
Adjustments to Additional Paid in Capital, Warrant Issued
Shares unissued (in shares)
Other assets
Operating expenses:
Total operating expenses
Operating Expenses
Amount excluded from calculation (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive Securities [Axis]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Loss Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Earnings Per Share, Diluted, Other Disclosure [Abstract]
Deemed dividend
Preferred Stock Redemption Premium
Class of Stock [Axis]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Common stock, par value (in dollars per share)
Ending balance
Beginning balance
Total stockholders' equity (deficit)
Equity, Attributable to Parent
Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,260,000 issued and outstanding at September 30, 2023 and December 31, 2022, liquidation value $1,260,000 at September 30, 2023
Common Stock [Abstract]
Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Equity Components [Axis]
Additional Paid-in Capital [Member]
Retained Deficit [Member]
Equity Component [Domain]
Common Stock Weighted average Grant Date fair Value (in dollars per share)
Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]
Deferred Bonus [Member]
Stock Options [Member]
Non-cash interest expense
Issuance of common stock from conversion of Series A convertible preferred stock
Stock-based compensation expense (in shares)
Exercised (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Issuance of common stock from conversion of Series A convertible preferred stock (in shares)
NONCASH FINANCING ACTIVITIES:
Stock Option Activity [Roll Forward]
Common Stock Warrants shares [Roll Forward]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Weighted Average Assumptions for Stock Options Granted [Abstract]
Fair Value Assumptions Before and After Extension of warrants [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Loss Per Share
Class of Stock [Line Items]
Schedule of Stock by Class [Table]
Leases [Abstract]
Commitments and contingencies (Note 10)
Adjustments to reconcile net loss to net cash flows from operating activities:
Long-term Debt, Type [Axis]
Accounts payable
Accrued expenses and other
Total
Accrued Liabilities, Current
Legal and accounting fees
Accrued dividends payable
Accrued compensation
Long-term Debt, Type [Domain]
Stock-based compensation expense
Galectin Sciences LLC
Prepaid expenses and other current assets
Series C 6% super dividend redeemable convertible preferred stock, redemption value
Increase (Decrease) in Temporary Equity [Roll Forward]
Series C 6% super dividend redeemable convertible preferred stock liquidation value
Assets
Assets, Fair Value Disclosure
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Measurement Frequency [Domain]
Fair Value Hierarchy and NAV [Domain]
Recurring [Member]
Common stock issued for dividends (in shares)
Income tax payment withholding
Proceeds from exercise of common stock purchase warrants
Shares withheld to cover income tax withholding (in shares)
Accrued Expenses and Other [Abstract]
Basis of Presentation and Liquidity [Abstract]
Ending balance (in shares)
Beginning balance (in shares)
Shares, Outstanding
Convertible note payable repayment
Fair Value Hierarchy and NAV [Axis]
Measurement Frequency [Axis]
Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis
Accrued Expenses
Commitments and Contingencies [Abstract]
Fair Value of Financial Instruments [Abstract]
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Stock Option Activity
Weighted Average Assumptions Used to Determine Fair Value of Options Granted
Stock-Based Compensation [Abstract]
Reclassification of accrued compensation to additional paid in capital
Basis of Presentation and Liquidity
Basis of Accounting [Text Block]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Key Assumptions Used in Model at Inception
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Research and Development [Member]
Research and Development Expense [Member]
Convertible note principal
Payment of preferred stock dividends in common stock
Stock Issued
Derivative Instrument [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Exercised (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Share price (in dollars per share)
Closing price (in dollars per share)
Financial Instrument [Axis]
Ending balance
Beginning balance
Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at September 30, 2023 and December 31, 2022, redemption value: $8,203,000, liquidation value: $1,760,000 at September 30, 2023
Weighted Average Exercise Price [Abstract]
Granted (in dollars per share)
Exercised (in dollars per share)
Forfeited/cancelled (in dollars per share)
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]
Award Type [Axis]
Income Statement Location [Axis]
Income Statement Location [Domain]
Stock based compensation expense
Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense
Series A 12% convertible preferred stock, liquidation value
Credit Facility [Axis]
Credit Facility [Domain]
Expected life
Expected life of the options
Unrecognized compensation cost, recognition period
Conversion price (in dollars per share)
Derivative Contract [Domain]
Investments in and Advances to Affiliates [Line Items]
Schedule of Investments [Table]
IPR&D [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Change in fair value of derivative liabilities
Fair Value Adjustment
Fair Value Adjustment of Warrants
Additional short term borrowing interest rate
Term
Liabilities
Financial Liabilities Fair Value Disclosure
Unvested options (in shares)
Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]
Exercise price of warrant (in dollars per share)
Lease cost
Right to use lease asset
Maturity of Operating Lease [Abstract]
Discount rate on present value of lease payments
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Line Items]
Lease Commitments [Abstract]
NET DECREASE IN CASH AND CASH EQUIVALENTS
Amount expanded in cash
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
CASH AND CASH EQUIVALENTS, END OF PERIOD
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Total
Lessee, Operating Lease, Liability, to be Paid
2024
2025
2023
Maturity of Operating Lease
Present value of lease liability
Operating Lease, Liability
Current lease liability
Lease liability
Less imputed interest
Long term lease liability
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]
Leases
Galectin Sciences LLC [Abstract]
Measurement Input Type [Axis]
Conversion Price of Conversion Feature [Member]
Credit Adjusted Discount Rate [Member]
Dividend Rate [Member]
Term [Member]
Volatility [Member]
Risk Free Interest Rate [Member]
Stock Price [Member]
Measurement Input Type [Domain]
Key Assumptions [Abstract]
Derivative liability, measurement input
Derivative Liability, Measurement Input
Term of contract
Fair Value, Inputs, Level 1, 2 and 3 [Member]
Weighted average expiration term of warrants outstanding
Warrants and Rights Outstanding, Term
Warrants expiry date
Amortization of right to use lease asset
Title of Individual [Domain]
Richard E. Uihlein [Member]
Chief Executive Officer [Member]
Scenario [Domain]
Forecast [Member]
Scenario [Axis]
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Maximum [Member]
Minimum [Member]
Counterparty Name [Axis]
Counterparty Name [Domain]
Title of Individual [Axis]
Ownership [Axis]
Ownership [Domain]
Cover [Abstract]
Document Type
Document Quarterly Report
Document Transition Report
Entity Interactive Data Current
Amendment Flag
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Period End Date
Entity Registrant Name
Entity Central Index Key
Entity File Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Current Fiscal Year End Date
Entity Current Reporting Status
Entity Shell Company
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Common Stock, Shares Outstanding
Contract cancelation notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Contract Cancelation Notice Period
Contract cancelation notice period
Name of entity.
Galectin Sciences, LLC [Member]
Galectin Sciences, LLC [Member]
Name of counterparty. A counterparty is the other party that participates in a financial transaction.
SBH Sciences, Inc. [Member]
SBH [Member]
Capital contribution expense.
Capital Contribution Expense
Contribution for expenses
Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Warrant Two [Member]
Warrant Two [Member]
The amount of issuance of warrants.
Issuance of Warrants Value
Warrants issuance value
The percentage of exercise price per share or per unit of warrants equal to common stock.
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percentage Equal to Common Stock
Percentage of warrants equal to the closing price of common stock
Accrued, but unpaid interest on the debt instrument.
Debt Instrument, Accrued Interest
Accrued interest
Number of securities into which the class of additional warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
Class of Additional Warrant or Right, Number of Securities Called by Warrants or Rights
Warrants to purchase additional common stock (in shares)
Line of Credit, Related Party [Abstract]
Convertible Line of Credit - Related Party [Abstract]
Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Warrant Three [Member]
Warrant Three [Member]
Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Warrant One [Member]
Warrant One [Member]
Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs and other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Accrued Research and Development Costs and Other Current
Accrued research and development costs and other
Basis of Presentations and Liquidity [Abstract]
Basis of Presentation and Liquidity [Abstract]
An unsecured convertible promissory note is a debt obligation in which a company borrows money from an investor in exchange for a promise of repayment and an option to convert the outstanding principal into equity of the company upon some triggering event. Notes have a maturity date and bear interest.
Unsecured Convertible Promissory Note [Member]
Unsecured Convertible Promissory Note [Member]
Percentage of underlying the outstanding whole number of DSUs credited individuals during period.
Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Four
Percentage of DSUs shall be credited on March 1, 2025
Percentage of underlying the outstanding whole number of DSUs credited individuals during period.
Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Five
Percentage of DSUs shall be credited on Janurary 5, 2026
Percentage of underlying the outstanding whole number of DSUs credited individuals during period.
Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period One
Percentage of DSUs shall be credited on March 1, 2023
The deferred compensation arrangement with individual cash award granted paid in cash percentage.
Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Cash Percent
Percentage of base salary paid in cash
Percentage of underlying the outstanding whole number of DSUs credited individuals during period.
Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Two
Percentage of DSUs shall be credited on March 1, 2024
The deferred compensation arrangement with individual cash award granted paid in deferred stock units percentage.
Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Deferred Stock Units Percent
Percentage of base salary paid in deferred stock units
Percentage of underlying the outstanding whole number of DSUs credited individuals during period.
Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Three
Percentage of DSUs shall be credited on September 1, 2028
Restricted Stock Grants [Abstract]
Restricted Stock Grants [Abstract]
Free rent period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Free Rent Period
Free rent period
Number of operating leases during period.
Number of Operating Leases
Number of operating leases
Beneficial ownership percentage of the outstanding shares of the Company's Class A common stock that would allow warrants to be settled in cash upon the occurrence of a tender offer or exchange offer.
Beneficial Ownership Percentage
Beneficial ownership percentage
Class of security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Series B Warrants [Member]
Threshold period for extension of exercise date of common stock purchase warrants under purchase agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Threshold Period for Extension of Exercise Date of Purchase Warrants under Agreement
Threshold period for extension of exercise date of purchase warrants under purchase agreement
Threshold period for stock closing price in ten consecutive days under purchase warrants agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Threshold Period for Stock Closing Price in Ten Consecutive Days under Purchase Warrants Agreement
Threshold period for stock closing price in 10 consecutive days under purchase warrants agreement
Period of specified trading days that common stock price must exceed threshold price for specified number of trading days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Number of Trading Days to be Considered Stock Closing Price in Purchase Agreement
Number of consecutive trading days to be considered in purchase agreement
Number of prior notice days required that would bar the voluntary exercise of any warrants that would result in beneficial ownership beyond specified percentage, in P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Period of Prior Notice that Would Bar Voluntary Exercise of any Warrants
Period of prior notice that would bar voluntary exercise of any warrants
Change in fair value of the warrants immediately before the modification.
Before Modification [Member]
Before Modification [Member]
Change in fair value of the warrants immediately after the modification.
After Modification [Member]
After Modification [Member]
Name of beneficial owner.
10X Fund L.P [Member]
Name of beneficial ownership entity.
10X Fund L.P., and 10X Capital Management LLC [Member]
Agreement with a sales agent under which the Company may issue and sell shares of its common stock.
Two Thousand Twenty Market Agreement [Member]
2020 Market Agreement [Member]
Percentage of commission rate to be paid to sales agent in gross proceeds from the sale of common stock.
Commission Rate
Percentage of commission rate to be paid to sales agent
Amount of aggregate offering price of common stock which can be sold from time to time through the sales agent.
Aggregate Offering Price
Aggregate offering price
Outstanding nonredeemable series A and series C preferred stock or outstanding series A and series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.
Series A and Series C Preferred Stock [Member]
Series A and Series C Preferred Stock [Member]
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price
Granted (in dollars per share)
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price
Outstanding at end of period (in dollars per share)
Outstanding at beginning of period (in dollars per share)
Weighted average price at which option holders acquired shares when converting their stock options into shares.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price
Exercised (in dollars per share)
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
Share based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Forfeitures In Period Weighted Average Exercise Price
Forfeited/cancelled (in dollars per share)
Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price [Abstract]
The type of debt instrument.
April Convertible Promissory Note [Member]
April 2021 Note [Member]
A type of debt instrument.
September Convertible Promissory Note [Member]
September 2021 Note [Member]
The type of debt instrument.
December Convertible Promissory Note [Member]
December 2021 Note [Member]
The number of promissory notes evidenced by loans agreement.
Number of Promissory Notes Evidenced by Loans Agreement
Number of promissory notes evidenced by loans agreement
Contingent interest rate per quarter for funds borrowed, under the debt agreement.
Quarterly Interest Rate
Additional interest rate per quarter
Contingent interest rate per annum for funds borrowed, under the debt agreement.
Annual Interest Rate
Additional interest rate per annum from issuance date to maturity date period
Convertible Notes Payable, Related Party [Abstract]
Convertible Notes Payable - Related Party [Abstract]
The derivative liability of contingent interest September Note.
Contingent Interest, September Note [Member]
September Note [Member]
The derivative liability of contingent interest December Note.
Contingent Interest, December Note [Member]
December Note [Member]
The derivative liability of contingent interest April Note.
Contingent Interest, April Note [Member]
April Note [Member]
The entire disclosure for Equity warrants are instruments that bestow upon the holder of the instrument the right to buy a particular stock at a predetermined price within a stipulated time frame. ... This payment is to be adjusted against the final payment that needs to be paid in case the warrants are exercised.
Common Stock Warrants Disclosure [Text Block]
Common Stock Warrants
Common Stock Warrants [Abstract]
The fair value of common stock purchase warrants issued in connection with related party line of credit in noncash financing activities.
Common Stock Purchase Warrants Issued in Connection with Related Party Line of Credit
Common stock purchase warrants issued in connection with related party line of credit
Amount reclassified from accrued compensation to excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Reclassification Of Accrued Bonus To Additional Paid In Capital
Reclassification of accrued bonus to additional paid in capital
Amount of expense (income) related to adjustment to fair value of warrant liability.
Fair Value Adjustment of Warrant
Warrant modification
Warrant modification
Amount of paid and unpaid temporary equity dividends declared with the form of settlement in cash.
Temporary Equity Dividends
Series C super dividend redeemable convertible preferred stock dividend
Number of shares of Convertible preferred stock issued as dividends during the period. Excludes stock splits.
Convertible Preferred Stock Dividends, Shares
Series A 12% convertible preferred stock dividend (in shares)
Amount of paid and unpaid convertible preferred stock dividends declared with the form of settlement in cash.
Convertible Preferred Stock, Dividends
Series A 12% convertible preferred stock dividend
Number of shares of common stock issued as dividends for temporary equity during the period.
Temporary Equity Dividends, Shares
Series C super dividend redeemable convertible preferred stock dividend (in shares)
Equity impact of the value of stock issued from the exercise of warrants.
Stock Issued During Period Value Warrant Exercise
Issuance of common stock from exercise of warrants
Amount of increase (decrease) in additional paid in capital (APIC) resulting from the modification of warrants.
Adjustments to Additional Paid in Capital, Warrant Modification
Warrant modification
Number of new stock issued upon the exercise of warrants during the period.
Stock Issued During Period Shares Warrant Exercise
Issuance of common stock from exercise of warrants (in shares)
Number of shares of undesignated capital stock which are designated as common stock or preferred stock by board of directors.
Undesignated Capital Stock Shares Designated
Undesignated stock, shares designated (in shares)
The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.
Undesignated Capital Stock, Shares Authorized
Undesignated stock, shares authorized (in shares)
Face amount or stated value per share of undesignated capital stock.
Undesignated Capital Stock Par Value
Undesignated stock, par value (in dollars per share)
Aggregate par or stated value of shares which are not designated as common stock or preferred stock.
Undesignated Capital Stock Value
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at September 30, 2023 and December 31, 2022, respectively
Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
Convertible Note Payable and Accrued Interest Net of Debt Discount - Related Party Non-Current
Convertible notes payable and accrued interest, net of discounts - related party (Note 3)
Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as borrowing and accrued interest under line of credit related party excluding current portion.
Borrowing and Accrued Interest Under Line of Credit, Net of Debt Discount, Related Party Noncurrent
Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 9)